Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Drug Profile

Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Alternative Names: Live attenuated varicella vaccine - Sinovac Biotech/Dalian Vaccine Technology; Varicella zoster vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline; Sinovac (Dalian) Vaccine Technology
  • Developer Sinovac (Dalian) Vaccine Technology
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Varicella zoster virus infections

Most Recent Events

  • 19 Oct 2016 Sinovac completes phase I trial for for Varicella zoster virus infections in China
  • 01 Aug 2016 Phase-III clinical trials in Varicella zoster virus infections (Prevention, In volunteers, In children) in China (Parenteral) (NCT02981836)
  • 01 May 2016 Phase-I clinical trials in Varicella zoster virus infections (Prevention, In volunteers) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top